201. アンジェルマン症候群 Angelman syndrome Clinical trials / Disease details
臨床試験数 : 24 / 薬物数 : 35 - (DrugBank : 9) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 20
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03235037 (ClinicalTrials.gov) | November 26, 2013 | 28/7/2017 | Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome | Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome | Angelman Syndrome | Drug: Levodopa | Bennett Lavenstein | NULL | Completed | 18 Months | 16 Years | All | 10 | N/A | NULL |
| 2 | NCT01281475 (ClinicalTrials.gov) | January 2011 | 20/1/2011 | A Trial of Levodopa in Angelman Syndrome | A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome | Angelman Syndrome | Drug: Levodopa;Drug: Placebo Oral Capsule | Wen-Hann Tan | Rady Children's Hospital, San Diego;University of California, San Francisco;Baylor College of Medicine;Vanderbilt University Medical Center;Greenwood Genetic Center;Children's Hospital Medical Center, Cincinnati;Angelman Syndrome Foundation, Inc. | Completed | 4 Years | 12 Years | All | 67 | Phase 2/Phase 3 | United States |
| 3 | NCT00829439 (ClinicalTrials.gov) | January 2009 | 26/1/2009 | Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome | A Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman Syndrome | Angelman Syndrome | Drug: Levodopa/Carbidopa (4:1) | Boston Children’s Hospital | NULL | Completed | 4 Years | 12 Years | All | 16 | Phase 1 | United States |